

# Pharmacokinetics and Cognitive Side Effects of Cannabidiol In Adult Patients

Miss. Akanksha N. Mote, Miss. Pratiksha B. Bhise, Miss. Rasika D. Chavan,  
Miss. Prapti P. Patil, Manohar D. Kengar

Nootan College of Pharmacy, Kavathe Mahankal, Maharashtra, India

**Abstract:** Nowadays, there's a great interest in the possible medical use of cannabidiol (CBD), a non-intoxicating cannabinoid. Productive pharmacological investigation on CBD passed in the 1970s and boosted freshly with multiple discoveries about the Endocannabinoid System. The World Health Organization (WHO) considers registering cannabis and cannabinoids. CBD use around the world is developing for conditions that need scientific proof of the medicine's efficacy. The effect of cannabinoids on anesthesia is mentioned compactly. Important advances have taken place in cannabinoid study over the last many times and have conducted to the discovery of new ligands. The possible clinical operations of these ligands and the direction of coming study are agitated.

**Background:** Cannabidiol is being coursed as a medicinal treatment for multiple conditions, generally by oral delivery. Creature studies suggest oral bioavailability is low, but literature in humans isn't sufficient. (1)

**Keywords:** Pharmacokinetics

## REFERENCES

- [1]. Systematic Review on the pharmacokinetics of Cannabidiol in humans .Sophie A. Millar 1\*, Nicole L. Stone1, Andrew S. Yates 2 and Saoirse E. O'Sullivan1
- [2]. Grlie L. A comparative study on some chemical and biological characteristics of various samples of cannabis resin. Bull Narcot1976; 14: 37-46
- [3]. Mehmedic Z, Chandra S, Slade D, et al. Potency trends of 9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. J Forensic Sci 2010; 55: 1209-17.
- [4]. Perez-Reyes M, Timmons MC, Davis KH, Wall ME. A comparison of the pharmacological activity in man of intravenously administered delta-9-tetrahydrocannabinol, cannabiol and cannabidiol. Experientia 1973; 29: 1368-9.
- [5]. Gaoni, Y.; Mechoulam, R. Isolation, structure, and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc., 1964, 86, 1646-1647. [http://dx.doi.org/10.1021/ja01062a046].
- [6]. Izzo, A. A., Borrelli, F., Capasso, R., Di Marzo, V., and Mechoulam, (2009). Non-psychoactive plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol. Sci. 30, 515-527. Doi: 10.1016/j.tips.2009.07.006
- [7]. Bergamaschi, M. M., Queiroz, R. H., Zuardi, A. W., and Crippa, J. A. (2011). Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr. Drug Saf. 6,237-249. Doi: 10.2174/157488611798280924.
- [8]. Hemp Business (2017). Hemp Business Journal. State of Hemp Market Report.
- [9]. Crippa, J. A., Derenusson, G. N., Ferrari, T. B., Wichert-Ana, L., Duran, F.L., Martin-Santos, R., et al. (2011). Neural basis of anxiolytic effects of Cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J. Psychopharmacol. 25, 121-130. Doi: 10.1177/0269881110379283.
- [10]. Adams R, Hunt M, Clark JH. Structure of cannabidiol, a product Isolated from the marihuana extract of Minnesota wild hemp. J Am Chem Soc 1940; 62: 196-200.
- [11]. Mechoulam R, Shvo Y. The structure of cannabidiol. Tetrahedron 1963; 19: 2073-8.
- [12]. Cunha JM, Carlini EA, Pereira AE, et al. Chronic administration of Cannabidiol to healthy volunteers and epileptic Pharmacology 1980; 21: 175-85.

- [13]. Zuardi AW, Crippa JA, Hallak JE, Moreira FA, Guimarães FS. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. *Braz J Med Biol Res* 2006; 39(4): 421-429.
- [14]. Zuardi AW. Cannabidiol: from an inactive cannabinoid to a drug With wide spectrum of action. *Rev Bras Psiquiatr* 2008; 30(3): 271-80.
- [15]. Mechoulam, R., Parker, L. A., and Gallily, R. (2002). Cannabidiol: an overview of some pharmacological aspects. *J. Clin. Pharmacol.* 42, 11S–19S. doi: 10.1002/j.1552-4604.2002.tb
- [16]. Zgair, A., Wong, J. C., Lee, J. B., Mistry, J., Sivak, O., Wasan, K. M., et al. (2016). Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines. *Am. J. Transl. Res.* 8, 3448–3458, 3448–3458. Bergamaschi MM, Queiroz RH, Zuardi AW, et al. Safety and side effects of cannabidiol, a Cannabis sativa constituent. *Curr Drug Saf.* 2011;6:237–249.
- [17]. Samara, E., M. Bialer, and R. Mechoulam. 1988. Pharmacokinetics of cannabidiol in Dogs. *Drug Metab Dispos* 16(3):469-72.
- [18]. Johansson, E., A. Ohlsson, J.E. Lindgren, S. Agurell, H. Gillespie, and L.E. Hollister. 1987. Single-dose kinetics of deuterium-labelled cannabidiol in man after intravenous administration and smoking. *Biomed Environ Mass Spectrom* 14(9):495-9.
- [19]. Brewster, M.E., E. Pop, R.L. Foltz, S. Reuschel, W. Griffith, S. Amselem, and A. Biegon. 1997. Clinical pharmacokinetics of escalating i.v. doses of dexanabinol (HU-211), a neuroprotectant agent, in normal volunteers. *Int J Clin Pharmacol Ther* 35(9):361-5.
- [20]. Wall, M.E., B.M. Sadler, D. Brine, H. Taylor, and M. Perez-Reyes. 1983. Metabolism, Disposition, and kinetics of delta-9-tetrahydrocannabinol, in men and women. *Clin Pharmacol Ther* 34(3):352-363.
- [21]. Ohlsson, A., J.E. Lindgren, S. Andersson, S. Agurell, H. Gillespie, and L.E. Hollister 1984. Single dose kinetics of cannabidiol in man. In *The Cannabinoids: Chemical, Pharmacologic, and Therapeutic Aspects*, edited by S. Agurell, W.L. Dewey, and R. Willette. New York: Academic Press.
- [22]. Agurell, W.L. Dewey, and R. Willette. New York: Academic Press. Agurell, S., S. Carlsson, J.E. Lindgren, A. Ohlsson, H. Gillespie, and L. Hollister. 1981. Interactions of delta 1-tetrahydrocannabinol with cannabidiol and cannabidiol following oral administration in man. Assay of cannabidiol and cannabidiol by mass fragmentography. *Experientia* 37(10):1090.
- [23]. Consroe, P., J. Laguna, J. Allender, S. Snider, L. Stern, R. Sandyk, K. Kennedy, and K. Schram. 1991. Controlled clinical trial of cannabidiol in Huntington's disease. *Pharmacol Biochem Behav* 40(3):701-8.
- [24]. Alozie, S.O., B.R. Martin, L.S. Harris, and W.L. Dewey. 1980. 3H-delta 9-Tetrahydro-cannabinol, 3H-cannabinol and 3H-cannabidiol: penetration and regional distribution in rat brain. *Pharmacol Biochem Behav* 12(2):217-21.
- [25]. Wall, M.E., D.R. Brine, and M. Perez-Reyes. 1976. Metabolism of cannabinoids in man. In *Pharmacology of Marijuana*, edited by M.C. Braude, S.
- [26]. Rosenkrantz, H.; Fleischman, R.W.; Grant, R.J. Toxicity of short-term administration of cannabinoids to rhesus monkeys. *Toxicol. Appl. Pharmacol.*, 1981, 58, 118-131.
- [27]. Greenwich Biosciences. Epidiolex, full prescribing information. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2018/21036\\_5lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/21036_5lbl.pdf) (Accessed 12 March, 2019).
- [28]. Thiele, E.A.; Marsh, E.D.; French, J.A.; Mazurkiewicz-Beldzinska, M.; Benbadis, S.R.; Joshi, C.; Lyons, P.D.; Taylor, A.; Roberts, C.; Sommerville, K.; GWPCARE4 Study Group. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet*, 2018, 391, 1085-1096.
- [29]. Devinsky, O.; Marsh, E.; Friedman, D.; Thiele, E.; Laux, L.; Sulli-Van, J.; Miller, I.; Flamini, R.; Wilfong, A.; Filloux, F.; Wong, M.; Tilton, N.; Bruno, P.; Bluvstein, J.; Hedlund, J.; Kamens, R.; Ma-Clean, J.;

- Nangia, S.; Singhal, N.S.; Wilson, C.A.; Patel, A.; Cilio, M.R. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. *Lancet Neurol.*, 2016, 15, 270-278.
- [30]. Neale, M. Efficacy and safety of cannabis for treating children with refractory epilepsy. *Nurs. Child. Young People*, 2017;
- [31]. Landrigan J, Bessenyei K, Leitner D, Yakovenko I, Fisk JD, Prentice JL. A systematic review of the effects of cannabis on cognition in people with multiple sclerosis. *Mult Scler Relat Disord.* 2022;57:1033multiple sclerosis. *Mult Scler Relat Disord.* 2022;57:103338 .
- [32]. Feinstein A, Meza C, Stefan C, Staines RW. Coming of cannabis: a cognitive and magnetic resonance imaging study in patients with multiple Sclerosis. *Brain.* 2019;142(9):2800–12 .
- [33]. Wilsey B, Marcotte T, Tsodikov A, Millman J, Bentley H, Gouaux B, et al. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. *J Pain.* 2008;9(6):506–2neuropathic pain. *J Pain.* 2008;9(6):506–21.
- [34]. Wilsey B, Marcotte T, Deutsch R, Gouaux B, Sakai S, Donaghe H. Low-dose Vaporized cannabis significantly improves neuropathic pain. *J Pain.* 2013;14(2):136–48.
- [35]. Stockings E, Campbell G, Hall WD, Nielsen S, Zagic D, Rahman R, et al. Cannabis and cannabinoids for the treatment of people with chronic Non cancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. *Pain.* 2018;15 .
- [36]. Russo EB. Taming THC: potential cannabis synergy and Phytocannabinoid-terpenoid entourage effects. *Br J Pharmacol* 2011; 163(7): 1344-6 2011; 163(7): 1344-64.
- [37]. Kelly, T.H., R.W. Foltin, C.S. Emurian, and M.W. Fischman. 1993. Performance-based testing for drugs of abuse: dose and time profiles of marijuana, amphetamine, alcohol, and diazepam. *J Anal Toxicol* 17(5):264-72 .
- [38]. Harvey DJ, Samara E, Mechoulam R. Comparative metabolism of cannabidiol in dog, rat and man. *Pharmacol Biochem Behav.* 1991; 40(3): 523-340(3): 523-32.
- [39]. Bergamaschi MM, Queiroz RH, Zuardi AW, et al. Safety and side effects of cannabidiol, a Cannabis sativa constituent. *Curr Drug Saf.* 2011;6:237–249.
- [40]. Wachtel, S.R., M.A. ElSohly, S.A. Ross, J. Ambre, and H. De Wit. 2002. Comparison of the subjective effects of delta(9)-tetrahydrocannabinol and marijuana in humans. *Psychopharmacology* 161(4):331-9.
- [41]. Moher D, Liberati A, Tetzlaff J, Altman DG, Grp P, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Brit Med J.* 2009;339(7716):332-6.
- [42]. Moher, D., Liberati, A., Tetzlaff, J., and Altman, D. G. (2009). Preferred reporting Items for systematic reviews and meta-analyses: the PRISMA statement. *Ann. Int. Med.* 151, 264–269, w64. Doi: 10.7326/0003-4819-151-4-20090818000135 .
- [43]. National Institute for Health (2014). National Lung and Blood Institute Quality Assessment Tool for Before-After (Pre-Post) Studies with No Control Group.
- [44]. arons, L., and Graham, G. (2006). Sample size calculations Based on generalized estimating equations for population pharmacokinetic Experiments. *J. Biopharm. Stat.* 16, 135–150. Doi: 10.1080/10543400500508705 .
- [45]. Moher D, Liberati A, Tetzlaff J, Altman DG, The PG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med.* 2009;6(7):e1000097.
- [46]. A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans -Sophie A. Millar 1, Nicole L. Stone1, Andrew S. Yates 2 and Saoirse E. O’Sullivan1 ;published: 26 November 2018 .
- [47]. An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies Kerstin Iffland and Franjo Grotenhermen, 2017 .
- [48]. A systematic review of the effect of cannabidiol on cognitive function: relevance to schizophrenia ,2017 ; Ashleigh L. Ossborne , Nadia Solowij , Katrina Weston – Green .
- [49]. Safety and Side Effects of Cannabidiol, a Cannabis sativa Constituent , Mateus Machado Bergamaschi1,2, Regina Helena Costa Queiroz, José Alexandre S. Crippa, and Antonio Waldo Zuardi ,current drug safety ,2011 ,6 ,000-000.

- [50]. The effect of medical cannabis on cognitive functions: a systematic review ;Anders Wieghorst, Kirsten Kaya Roessler, Oliver Hendricks, and Tonny Elmoose ,Andersen; 2022
- [51]. Pharmacology and effects of cannabis :a brief review ;C. HEATHER ASTHION .
- [52]. Clinical pharmacokinetics of cannabinoids ;Franjo Grotenhermen ;January 2003.
- [53]. Human Pharmacokinetics and Adverse effects of Pulmonary and Intravenous THC-CBD Formulations .2018;Pascale Meyer, Manuela Langos ,Rudolf Brenneisen .